Pharmacokinetics of the immunosuppressant everolimus in maintenance renal transplant patients.
The novel macrocyclic immunosuppressant everolimus has been approved for use in renal and heart transplantation. The objective of this randomized, double-blind, placebo-controlled, dose-escalating Phase 1 study was to evaluate the pharmacokinetic profile of different dosing regimens of everolimus. Fifty-four subjects were randomized for 4-weeks treatment with everolimus (n = 44) or placebo (n = 10). Steady state was reached by day 4 of multiple dosing with evidence for dose-proportionality over the dose range tested. Systemic accumulation was 1.6- to 2.2-fold with multiple dosing. Steady-state predose trough concentrations were well correlated with AUC (r = 0.87, p < 0.001). Within-subject coefficients of variation for the tablet formulation ranged from 10-19% and between-subject coefficients from 34-60% for Cmax and AUC. There was no effect of common demographic parameters (age, sex, weight) on variability in steady-state exposure. These results support the clinical use of everolimus in renal transplantation.
Budde
K
K
Department of Nephrology, Charité University Hospital, Schumannstr. 20-21, D-10117 Berlin, Germany. klemens.budde@charite.de
Fritsche
L
L
Waiser
J
J
Glander
P
P
Slowinski
T
T
Neumayer
H-H
HH
D019540:Area Under Curve; D001682:Biological Availability; D015331:Cohort Studies; D003710:Demography; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008657:Metabolic Clearance Rate; D010919:Placebos; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000493:pharmacokinetics* / Q000627:therapeutic use
D007166:Immunosuppressive Agents; D010919:Placebos; D000068338:Everolimus; D020123:Sirolimus